Hamid, Omid
Robert, Caroline
Ribas, Antoni
Hodi, F. Stephen
Walpole, Euan
Daud, Adil
Arance, Ana S.
Brown, Ewan
Hoeller, Christoph
Mortier, Laurent
Schachter, Jacob
Long, Jianmin
Ebbinghaus, Scot
Ibrahim, Nageatte
Butler, Marcus
Article History
Received: 8 November 2017
Revised: 16 May 2018
Accepted: 9 July 2018
First Online: 11 September 2018
Competing interests
: O.H. reports personal fees for serving as a consultant to Amgen, Novartis, Roche, Bristol-Myers Squib (BMS), and Merck Sharp & Dohme (MSD), as a speaker for Amgen, BMS, Genentech, and Novartis, and support for contracted research from Astra Zeneca, BMS, Celldex, Genentech, Immunocore, Incyte, MSD, Merck Serono, MedImmune, Novartis, Pfizer, Rinat, and Roche. C.R. reports personal fees from serving on advisory boards for BMS. A.R. reports personal fees for serving as a consultant to MSD, and for serving as an SAB member for Kite Pharma, Five Prime, CytomX, Compugen, and Advaxis. F.S.H. reports grants to his institution from MSD, personal fees for serving as a consultant to Amgen, BMS, Celldex, EMD Serono, Genentech, and MSD, and royalties from a pending patent for MICA-related disorders. E.W. reports grants from MSD, Merck Serono, and Roche. A.D. reports personal fees from Novartis, Pfizer, Genentech, BMS, MSD, grants from MSD, and stock in OncoSec. C.H. reports personal fees from MSD, BMS, Amgen, Novartis, Roche, Pierre Fabre, and Incyte. L.M. reports personal fees from medical board with MSD France. J.S. reports personal fees and fees from serving as an SAB member for BMS and MSD. J.L., S.E., and N.I. are employees of MSD. J.L. and S.E. hold stock in MSD. N.I. holds stock in MSD and GSK. M.B. reports personal fees as an advisory board member from BMS, Novartis, Immunocore, Immunovaccine, EMD Serono, Turnstone, and MSD. A.S.A. and E.B. report no competing interests.
: This study and assistance with manuscript editing were funded by Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
: Protocols for the studies were approved by institutional review boards at each site. All patients provided written informed consent.
: All authors revised and critically reviewed this work and had final approval of the submitted manuscript.
: Merck Sharp & Dohme's (a subsidiary of Merck & Co., Inc., Kenilworth, NJ) data sharing policy, including restrictions, is available at ExternalRef removed. Requests for access to the clinical study data can be submitted through the EngageZone site or via email to dataaccess@merck.com.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).